FDA Grants Breakthrough Therapy Designation to Bristol-Myers Squibb’s HIV Candidate

Bristol-Myers Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients.

» Read more

New Antibody Shows Promise in Treating HIV

2000px-Red_Ribbon.svgAn experimental antibody therapy has shown promise in suppressing HIV infection, bringing optimism to the HIV field and suggesting new strategies for fighting or even preventing HIV.

Rockefeller University researchers have found that an experimental therapy, part of a new generation of so-called broadly neutralizing antibodies, can dramatically reduce the amount of virus present in a patient’s blood. The study was published this week in Nature.

» Read more